Clinical Trials Directory

Trials / Completed

CompletedNCT05634551

Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status

Status
Completed
Phase
Study type
Observational
Enrollment
15 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To better understand your feelings and expectations about immunotherapy

Detailed description

Primary Objective: 1\. To compare expectations of survival benefit from immunotherapy between advanced cancer patients with poor performance status (PS) and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of survival beyond 2 years. Secondary Objectives: 1. To compare expectations of therapeutic benefit of immunotherapy between advanced cancer patients with poor PS and their oncologists. We hypothesize that, compared to their oncologists, patients will have expectations for greater likelihood of cure, quality of life improvement, and lower likelihood of adverse events. 2. To qualitatively describe the priorities and preferences for information of advanced cancer patients with poor PS when considering immunotherapy treatment. 3. To evaluate the associations between discrepant expectations with patients' sociodemographic and clinical characteristics. 4. To compare patient and oncologist expectations with actual treatment outcomes and survival.

Conditions

Interventions

TypeNameDescription
BEHAVIORALQuestionnairesParticipants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
BEHAVIORALInterviewThe interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)

Timeline

Start date
2023-02-09
Primary completion
2024-08-02
Completion
2024-08-02
First posted
2022-12-02
Last updated
2024-08-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05634551. Inclusion in this directory is not an endorsement.